Introduction to Dayglim M 2mg Tablet

Dayglim M 2mg Tablet is a medication combining Glimepiride and Metformin, which are antidiabetic agents. This tablet is used to manage type 2 diabetes mellitus when diet, exercise, and a single agent are insufficient for controlling blood sugar levels. Type 2 diabetes occurs when the body either does not produce enough insulin or does not use insulin effectively. Symptoms can include:

Excessive urination
Excessive thirst
Hunger
Fatigue
Blurred vision

Glimepiride helps lower blood sugar by increasing insulin production in the pancreas and enhancing the body’s use of insulin. Metformin reduces the amount of sugar released into the blood by the liver. Along with taking Dayglim M 2mg Tablet, regular exercise and a proper diet are crucial for achieving the best results.

Dayglim M 2mg Tablet is used for?

Manages type 2 diabetes mellitus when diet, exercise, and a single agent are not enough for adequate glycemic control.

How Dayglim M 2 mg Tablet Works

Glimepiride: Increases insulin production from the pancreas to lower blood glucose.
Metformin: Lowers glucose production in the liver, delays glucose absorption from the intestine, and increases the body’s sensitivity to insulin.

How to Use Dayglim M 2mg Tablet

Dosage: Follow your physician’s advice on the correct dose and duration.
Administration: Swallow the tablet with a glass of water without crushing or chewing it.
Discontinuation: Do not stop taking the tablet without consulting your doctor.

Overdosage

If an overdose occurs, contact your doctor immediately or visit the nearest hospital. Symptoms of overdose include the risk of low blood sugar levels and life-threatening lactic acidosis, which can present as:

Vomiting
Stomach pain with muscle cramps
General unwellness with severe tiredness
Low body temperature
Slow heartbeat
Difficulty breathing

Side Effects of Dayglim M 2mg Tablet

Common Side Effects:

Taste disturbance
Nausea
Diarrhea
Vomiting
Stomach pain
Loss of appetite

Rare Side Effects:

Low blood sugar levels (hypoglycemia)
Signs of reduced red blood cells (pale skin, weakness, breathlessness), platelets (easy bleeding or bruising), or white blood cells (repeated infections)
Decreased vitamin B12 levels
Skin rashes, redness, itching, and hives

Alternative Medicines of Dayglim M 2mg

At 24×7 Pharma, a cheap online pharmacy has a various alternative medicines of Dayglim M 2mg, including Glimepiride and Metformin ingredient, such as:

Storage Information

Keep the tablet out of reach of children.
Store at a temperature below 25°C.

FAQs About Dayglim M 2 mg Tablet

Can I drive or handle machines after taking Dayglim M Tablet?

Avoid driving or operating machines if you experience low or high blood sugar levels, which can cause dizziness, tiredness, shaking, or visual problems. Consult your doctor before taking Dayglim M Tablet.

Is Dayglim M 2mg Tablet safe for patients with kidney problems?

Dayglim M Tablet is not recommended for patients with severe kidney disease. It should be used cautiously in patients with kidney issues, and the dose may be adjusted based on kidney function. Consult your doctor before taking this medication.

Can I consume alcohol while taking Dayglim M Tablet?

Avoid alcohol during treatment with Dayglim M Tablet as it can alter the blood sugar-lowering effect and increase the risk of lactic acidosis. Consult your doctor for advice.

References :

Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea
Hye-Soon Kim, Doo-Man Kim, Bong-Soo Cha, Tae Sun Park, Kyoung-Ah Kim, Dong-Lim Kim, Choon Hee Chung, Jeong-Hyun Park, Hak Chul Jang, Dong-Seop Choi
J Diabetes Investig. 2014 Nov;5(6):701-8. doi: 10.1111/jdi.12201. Epub 2014 Mar 16.
https://pubmed.ncbi.nlm.nih.gov/25422771/
Glimepiride Versus Metformin as Monotherapy in Pediatric Patients With Type 2 Diabetes: A randomized, single-blind comparative study
Michael Gottschalk, MD; Thomas Danne, MD; Aleksandra Vlajnic, MD; José F. Cara, MD
APRIL 01 2007
https://diabetesjournals.org/care/article/30/4/790/25722/Glimepiride-Versus-Metformin-as-Monotherapy-in